Calcitonin gene-related peptide (CGRP) inhibitors hold the promise of helping migraine sufferers prevent attacks and maintain functioning. For employers, considering that migraine is both underdiagnosed and undertreated, the potential to reduce lost productivity due to migraine is substantial.
On June 14, 2018, the California Technology Assessment Forum (CTAF) convened to review the Institute for Clinical and Economic Review (ICER) report on CGRP inhibitors for prevention of migraine headaches.
The report identifies the clinical benefits of preventive treatment with CGRP inhibitors, and discusses their cost effectiveness under a variety of scenarios.
During the public commentary session, Brian Gifford, IBI's Director of Research and Analytics, presented findings from IBI's research showing the impact of migraine on health care spend, sick days, disability leaves and job performance.
The comments drive home the point that as employers consider how to incorporate promising new treatment options into their healthcare benefit plans, they should take into account the business value that these therapies can deliver as well as their costs.
Video of the CTAF meeting can be viewed here. Dr. Gifford's comments close the public comments, beginning at about 2:15:55.